ADVANCED ACCELERATOR APPLICATIONS
Clinical Trials
30
Trial Phases
4 Phases
Drug Approvals
8
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (24 trials with phase data)• Click on a phase to view related trials
177Lu-PSMA-617 Managed Access Program for mCRPC Patients
- Conditions
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- Advanced Accelerator Applications
- Registration Number
- NCT04825652
Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs
- Conditions
- Gastroenteropancreatic Neuroendocrine Tumor
- Interventions
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Advanced Accelerator Applications
- Target Recruit Count
- 164
- Registration Number
- NCT04727723
- Locations
- 🇮🇹
Novartis Investigative Site, Torino, Italy
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
- Conditions
- PheochromocytomaGastroenteropancreatic Neuroendocrine TumorsParaganglioma
- Interventions
- Drug: Lutetium [177Lu] oxodotreotide/dotatate
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- Advanced Accelerator Applications
- Target Recruit Count
- 11
- Registration Number
- NCT04711135
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
🇺🇸Cincinnati Children's Hospital, Cincinnati, Ohio, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
- Conditions
- Gastroenteropancreatic Neuroendocrine Tumors
- Interventions
- Drug: arginine/lysine
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Advanced Accelerator Applications
- Target Recruit Count
- 42
- Registration Number
- NCT04524442
- Locations
- 🇮🇹
Istituto Europeo di Oncologia, Milan, MI, Italy
🇳🇱Erasmus University Medical Center, Rotterdam, GD, Netherlands
🇵🇱Gammed-Centrum Diagnostyczno-Lecznicze, Warsaw, Poland
Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
- Conditions
- Gastro-enteropancreatic Neuroendocrine Tumor
- Interventions
- Drug: 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot)Drug: 2.5% Lys-Arg sterile amino acid solution
- First Posted Date
- 2019-06-03
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Advanced Accelerator Applications
- Target Recruit Count
- 226
- Registration Number
- NCT03972488
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸USF - H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸University of Iowa Hospitals and Clinics - Oncology, Iowa City, Iowa, United States
- Prev
- 1
- 2
- 3
- 4
- Next
News
Radionuclide Therapy Shows Promise in Advanced Prostate Cancer Treatment
Radionuclide therapies are emerging as promising options for treating metastatic castration-resistant prostate cancer (mCRPC), especially after resistance to standard treatments.